← Leaderboards
Bernard E. Weissman
Univ Of North Carolina Chapel Hill
$16,032,468
Attributed
$20,319,117
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,319,117 · 18
By mechanism
R01$12,061,088 · 8
P30$5,912,114 · 7
T32$2,187,550 · 2
R21$158,365 · 1
Top collaborators
- David Huntsman7 shared
- Michael Benjamin Major7 shared
- Jeffrey M. Trent7 shared
- Victoria Lin Bae-Jump2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Elias Rosen$3,101,084
- Daniel E Michaud$205,141
- Henry Shelton Earp$37,241,767
- Michael Benjamin Major$9,815,030
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorGenetically Engineered MouseMouse ModelComplexAnimal ModelAnimalsCellsMemberTrainingPhenotypeTechnologyFundingCell LineGene ExpressionMutationResearch PersonnelLaboratoriesMalignant Neoplasm Of OvaryCancer CenterFacultyReagentGene TargetingProteins
Grant awards (76)
Drugging NRF2 to improve radiation therapy in head and neck squamous cell carcinoma$647,754
R01 · FY2025 · CA
Animal Models$359,374
P30 · FY2025 · CA · contact PI
Enhancement training for the next generation of translational Ph.D. scientists$196,444
T32 · FY2025 · GM · contact PI
Cancer Research Career Enhancement and Related Activities$187,328
P30 · FY2025 · CA · contact PI
Identifying the effects of NRF2 signaling on lung squamous cell carcinoma development$158,365
R21 · FY2025 · CA · contact PI
Animal Models$315,075
P30 · FY2024 · CA · contact PI
Enhancement training for the next generation of translational Ph.D. scientists$203,008
T32 · FY2024 · GM · contact PI
Animal Models$350,086
P30 · FY2023 · CA · contact PI
The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma$493,661
R01 · FY2022 · CA
Animal Models$350,086
P30 · FY2022 · CA · contact PI
The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma$503,737
R01 · FY2021 · CA
Cancer Epigenetics Training Grant$413,934
T32 · FY2021 · CA · contact PI
Animal Models$350,086
P30 · FY2021 · CA · contact PI
The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma$517,517
R01 · FY2020 · CA
Cancer Epigenetics Training Grant$425,995
T32 · FY2020 · CA · contact PI
Animal Models$312,514
P30 · FY2020 · CA · contact PI
The Tumor Suppressor Role of SMARCA4 in SCCOHT$576,025
R01 · FY2019 · CA · contact PI
The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma$485,161
R01 · FY2019 · CA · contact PI
Cancer Epigenetics Training Grant$376,251
T32 · FY2019 · CA · contact PI
Animal Models$302,923
P30 · FY2019 · CA · contact PI
The Tumor Suppressor Role of SMARCA4 in SCCOHT$714,783
R01 · FY2018 · CA · contact PI
The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma$500,167
R01 · FY2018 · CA · contact PI
Cancer Epigenetics Training Grant$385,767
T32 · FY2018 · CA · contact PI
Animal Models$312,517
P30 · FY2018 · CA · contact PI
The Tumor Suppressor Role of SMARCA4 in SCCOHT$81,362
R01 · FY2018 · CA · contact PI
Animal Models$2,967
P30 · FY2018 · CA · contact PI
Animal Models$2,103
P30 · FY2018 · CA · contact PI
Animal Models$1,368
P30 · FY2018 · CA · contact PI
The Tumor Suppressor Role of SMARCA4 in SCCOHT$718,667
R01 · FY2017 · CA · contact PI
Animal Models$306,588
P30 · FY2017 · CA · contact PI
Cancer Epigenetics Training Grant$186,151
T32 · FY2017 · CA · contact PI
The Tumor Suppressor Role of SMARCA4 in SCCOHT$81,362
R01 · FY2017 · CA · contact PI
The Tumor Suppressor Role of SMARCA4 in SCCOHT$781,296
R01 · FY2016 · CA · contact PI
Animal Models$308,421
P30 · FY2016 · CA · contact PI
The Tumor Suppressor Role of SMARCA4 in SCCOHT$697,118
R01 · FY2015 · CA · contact PI
Animal Models Core Facility$284,815
P30 · FY2015 · CA · contact PI
Animal Models Core Facility$281,059
P30 · FY2014 · CA · contact PI
Animal Models Core Facility$281,540
P30 · FY2013 · CA · contact PI
Animal Models Core Facility$286,646
P30 · FY2012 · CA · contact PI
Role of hsnf5/BAF47 Loss in Human Cancer Development$283,306
R01 · FY2012 · CA · contact PI
Role of hsnf5/BAF47 Loss in Human Cancer Development$40,657
R01 · FY2012 · CA · contact PI
Animal Models Core Facility$2,552
P30 · FY2012 · CA · contact PI
Animal Models Core Facility$291,504
P30 · FY2011 · CA · contact PI
Role of hsnf5/BAF47 Loss in Human Cancer Development$258,378
R01 · FY2011 · CA · contact PI
Role of hsnf5/BAF47 Loss in Human Cancer Development$37,639
R01 · FY2011 · CA · contact PI
SWI/SNF complex loss facilitates gene silencing during NSCLC development$307,100
R01 · FY2010 · CA · contact PI
Role of hsnf5/BAF47 Loss in Human Cancer Development$268,981
R01 · FY2010 · CA · contact PI
SWI/SNF complex loss facilitates gene silencing during NSCLC development$307,100
R01 · FY2009 · CA · contact PI
Role of hsnf5/BAF47 Loss in Human Cancer Development$268,981
R01 · FY2009 · CA · contact PI
CORE--ANIMAL PROCEDURES$142,768
P30 · FY2009 · CA · contact PI
CORE--ANIMAL PROCEDURES$142,924
P30 · FY2008 · CA · contact PI
SWI/SNF Chromatin Remodeling Loss and Human Cancer$274,906
R01 · FY2007 · CA · contact PI
CORE--ANIMAL PROCEDURES$136,187
P30 · FY2007 · CA · contact PI
Role of hsnf5/BAF47 Loss in Human Cancer Development$22,033
R01 · FY2007 · CA · contact PI
SWI/SNF Chromatin Remodeling Loss and Human Cancer$283,117
R01 · FY2006 · CA · contact PI
CORE--ANIMAL PROCEDURES$64,641
P30 · FY2006 · CA · contact PI
Role of hsnf5/BAF47 Loss in Human Cancer Development$36,500
R01 · FY2006 · CA · contact PI
SWI/SNF Chromatin Remodeling Loss and Human Cancer$289,930
R01 · FY2005 · CA
Role of hsnf5/BAF47 Loss in Human Cancer Development$256,674
R01 · FY2005 · CA
CORE--ANIMAL PROCEDURES$62,758
P30 · FY2005 · CA
SWI/SNF Chromatin Remodeling Loss and Human Cancer$289,930
R01 · FY2004 · CA
Role of hsnf5/BAF47 Loss in Human Cancer Development$256,674
R01 · FY2004 · CA
SWI/SNF Chromatin Remodeling Loss and Human Cancer$312,180
R01 · FY2003 · CA
Role of hsnf5/BAF47 Loss in Human Cancer Development$291,873
R01 · FY2003 · CA
Role of hsnf5/BAF47 Loss in Human Cancer Development$278,924
R01 · FY2002 · CA
CORE--TISSUE CULTURE FACILITY$157,506
P30 · FY2002 · CA
ISOLATION OF A SECOND WILMS TUMOR SUPPRESSOR GENE$276,248
R01 · FY2001 · CA
CORE--TISSUE CULTURE FACILITY$158,272
P30 · FY2001 · CA
CORE--TISSUE CULTURE FACILITY$157,506
P30 · FY2001 · CA
ISOLATION OF A SECOND WILMS TUMOR SUPPRESSOR GENE$66,470
R01 · FY2001 · CA
ISOLATION OF A SECOND WILMS TUMOR SUPPRESSOR GENE$268,205
R01 · FY2000 · CA
MOLECULAR AND GENETIC ANALYSIS OF THE EEC SYNDROME$220,202
R01 · FY2000 · DE
ISOLATION OF A SECOND WILMS TUMOR SUPPRESSOR GENE$66,470
R01 · FY2000 · CA
CORE--TISSUE CULTURE FACILITY$0
P30 · FY2000 · CA
CORE--ANIMAL EXPERIMENTATION$0
P30 · FY2000 · CA
CORE--TISSUE CULTURE FACILITY$0
P30 · FY2000 · CA